Published in Br J Pharmacol on June 01, 1977
Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol (1969) 2.61
Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. Eur J Pharmacol (1969) 2.26
Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats. Endocrinology (1972) 1.29
Application of steady-state kinetics to the study of catecholamine turnover after monoamine oxidase inhibition or reserpine administration. J Pharmacol Exp Ther (1968) 0.95
Early events in preprotein recognition in E. coli: interaction of SRP and trigger factor with nascent polypeptides. EMBO J (1995) 2.38
Signal peptides: exquisitely designed transport promoters. Mol Microbiol (1994) 2.28
Inositol phospholipid hydrolysis in rat cerebral cortical slices: I. Receptor characterisation. J Neurochem (1984) 2.26
An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun (1996) 1.99
Nascent membrane and presecretory proteins synthesized in Escherichia coli associate with signal recognition particle and trigger factor. Mol Microbiol (1997) 1.85
Suggestions on the pharmacological actions of ethinyloestradiol and progesterone on the control of monoamine metabolism in three regions from the brains of gonadectomized male and female mice and the possible clinical significance. Arch Int Pharmacodyn Ther (1974) 1.71
The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther (1997) 1.61
The effects of some hallucinogenic drugs upon the metabolism of noradrenaline. Life Sci (1969) 1.46
No role for phospholipase A2 and protein kinase C in the potentiation by alpha-adrenoceptors of beta-adrenoceptor-mediated cyclic AMP formation in rat brain. J Neurochem (1989) 1.45
The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.44
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci (1998) 1.44
Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology (2009) 1.39
Social isolation in the young rat: neurochemical effects of treatment with a long-acting neuroleptic, alpha-flupenthixol decanoate [proceedings]. Br J Pharmacol (1978) 1.38
Artificial transmembrane segments. Requirements for stop transfer and polypeptide orientation. J Biol Chem (1995) 1.38
Safety of amoxapine. Lancet (1989) 1.37
'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci (1998) 1.37
A fluorescence assay to monitor vesicle fusion and lysis. J Biol Chem (1982) 1.34
Idealization of the hydrophobic segment of the alkaline phosphatase signal peptide. Nature (1986) 1.34
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol (2000) 1.32
A non-invasive instrument for clinical assessment of the pre-corneal tear film stability. Curr Eye Res (1985) 1.27
Titration of protein transport activity by incremental changes in signal peptide hydrophobicity. Biochemistry (1993) 1.26
Some effects of a new tetracyclic anti-depressant compound, Org GB 94, on the metabolism of monoamines in the rat brain. Psychopharmacologia (1974) 1.26
Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol (1997) 1.26
The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther (1999) 1.23
Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol Sci (1998) 1.20
Studies on the adenosine-receptor mediating the augmentation of histamine-induced inositol phospholipid hydrolysis in guinea-pig cerebral cortex. Br J Pharmacol (1987) 1.19
Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology (2003) 1.17
Inositol phospholipid hydrolysis in rat cerebral cortical slices: II. Calcium requirement. J Neurochem (1984) 1.16
Synthetic signal peptides specifically recognize SecA and stimulate ATPase activity in the absence of preprotein. J Biol Chem (1998) 1.16
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry (2009) 1.16
Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol Biochem Behav (1998) 1.15
Signal peptide determinants of SecA binding and stimulation of ATPase activity. J Biol Chem (2000) 1.15
Differences in the adenosine receptors modulating inositol phosphates and cyclic AMP accumulation in mammalian cerebral cortex. Br J Pharmacol (1989) 1.15
5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. J Pharmacol Exp Ther (1985) 1.15
Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. J Neurochem (1988) 1.14
Rodent models of alcoholism: a review. Alcohol Alcohol (1989) 1.14
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
Some neurochemical effects of amphetamine, methylamphetamine and p-bromomethylamphetamine in the rat. Br J Pharmacol (1971) 1.14
Cannabinoids and PPARalpha signalling. Biochem Soc Trans (2006) 1.13
Surface engineering of living myoblasts via selective periodate oxidation. Biotechnol Bioeng (2003) 1.13
Mapping of nucleoside phosphorylase (Np-1) and esterase 10 (Es-10) on mouse chromosome 14. Biochem Genet (1977) 1.11
Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur J Pharmacol (1998) 1.10
Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol (2001) 1.09
Cross-talk between different receptor-effector systems in the mammalian CNS. Cell Signal (1989) 1.09
Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) (2000) 1.09
Functional limits of conformation, hydrophobicity, and steric constraints in prokaryotic signal peptide cleavage regions. Wild type transport by a simple polymeric signal sequence. J Biol Chem (1991) 1.08
Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem (1999) 1.07
Detergent effects on enzyme activity and solubilization of lipid bilayer membranes. Biochim Biophys Acta (1983) 1.07
Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem (1997) 1.07
Dopaminergic and serotonergic function following isolation rearing in rats: study of behavioural responses and postmortem and in vivo neurochemistry. Pharmacol Biochem Behav (1992) 1.07
Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology (1999) 1.06
Changes in brain monoamine concentrations during the oestrous cycle in the mouse: possible pharmacological implications. J Pharm Pharmacol (1971) 1.06
Sendai virus-mediated lysis of liposomes requires cholesterol. Proc Natl Acad Sci U S A (1983) 1.05
Effect of fluorescein instillation on the pre-corneal tear film stability. Curr Eye Res (1985) 1.05
Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci (2008) 1.04
Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol (2004) 1.04
Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology (2003) 1.04
Role of gap junctions in endothelium-derived hyperpolarizing factor responses and mechanisms of K(+)-relaxation. Eur J Pharmacol (2000) 1.03
An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience (1998) 1.03
Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol (1997) 1.02
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun (2005) 1.01
Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci (2000) 1.01
Characterization of a fluorescence assay to monitor changes in the aqueous volume of lipid vesicles. Anal Biochem (1983) 1.00
Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther (1990) 1.00
Dihydropyridine calcium channel activators and antagonists influence depolarization-evoked inositol phospholipid hydrolysis in brain. Eur J Pharmacol (1985) 0.99
Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem (1998) 0.98
The effects of some hallucinogenic drugs upon the metabolism of 5-hydroxy-tryptamine in the brain. Life Sci (1969) 0.98
Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol (1996) 0.98
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci (2004) 0.97
A comparison of A2 adenosine receptor-induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta. Br J Pharmacol (1994) 0.97
Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. J Pharmacol Exp Ther (1987) 0.96
Polymeric sequences reveal a functional interrelationship between hydrophobicity and length of signal peptides. J Biol Chem (1990) 0.96
Examination of the role of inhibition of cyclic AMP in alpha 2-adrenoceptor mediated contractions of the porcine isolated palmar lateral vein. Br J Pharmacol (1995) 0.96
Signal peptide cleavage regions. Functional limits on length and topological implications. J Biol Chem (1994) 0.96
Toxicity of antidepressants. Lancet (1986) 0.96
Changes in brain monoamine metabolism associated with CO2-induced amnesia in rats. Br J Pharmacol (1973) 0.95
Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol (1981) 0.94
A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex. Br J Pharmacol (1994) 0.94
Adenosine receptor-induced second messenger production in adult guinea-pig cerebellum. Br J Pharmacol (1993) 0.94
Agonist-induced changes in [Ca2+]i in N1E-115 cells: differential effects of bradykinin and carbachol. Eur J Pharmacol (1992) 0.94
Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci (1999) 0.94
The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry (2006) 0.94
The effect of a new tetracyclic anti-depressant compound, Org GB 94, on the turnover of dopamine, noradrenalin and serotonin in the rat brain. Arch Int Pharmacodyn Ther (1973) 0.94
Physical and conformational properties of synthetic idealized signal sequences parallel their biological function. Biochemistry (1995) 0.94
The effect of a tetracyclic antidepressant compound, Org GB94, on the turnover of biogenic amines in rat brain. Biochem Pharmacol (1976) 0.94
Alpha 1-adrenoceptor-mediated inositol phospholipid hydrolysis in rat cerebral cortex: relationship between receptor occupancy and response and effects of denervation. Eur J Pharmacol (1985) 0.94
Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br J Pharmacol (2001) 0.93
Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord (1994) 0.93
The acute effects of oestrogen and progesterone on the monoamine levels of the brain of ovariectomised rats. Psychopharmacologia (1971) 0.92
Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.92
Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology (1998) 0.92
Receptors and phosphoinositide metabolism in the central nervous system. Biochem Pharmacol (1986) 0.91
Pirenzepine indicates heterogeneity of muscarinic receptors linked to cerebral inositol phospholipid metabolism. Neuropharmacology (1985) 0.91